ESCMID works throughout the year to propose and endorse quality guidelines to members and the global professional community. Below is a list of guidance documents that are currently under development. Explore the details of each guidance document and follow the evolution of their progress via the links provided.
The status of each project is defined based on the steps of the GIN-McMaster Guideline Development Checklist available here.
|
Title |
Chair |
Approval Date |
Status |
Website |
|---|---|---|---|---|
|
Approach to suspected antibiotic allergy |
Mark de Boer, Netherlands |
March 2023 |
Developing Recommendations and Determining their Strength (EtDs) (Ongoing) |
|
|
Vaccination of the immunocompromised host |
Olivier Epaulard, France |
March 2023 |
Judging Quality, Strength or Certainty of a Body of Evidence (GRADE) (Ongoing) |
|
|
Dosing of antimicrobials in patients with renal impairment with or without RRT |
Thomas Tängdén, Sweden |
March 2023 |
Data extraction (Ongoing) |
|
|
OPENING Project: IncOrPorating Ethics iN ClINical Guidelines: Practical Indications |
Elda Righi, Italy |
October 2022 |
Summarising evidence and conclusions (Ongoing) |
|
|
ESCMID Consensus document for management of COVID-19 in immunocompromised patients |
Michele Bartoletti, Italy and Roy Chemaly, United States |
May 2022 |
Reporting and peer review(Ongoing) |
|
|
Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients |
Evelina Tacconelli, Italy |
December 2020 |
Risk of Bias assessment (Ongoing) |
|
|
Influenza management and treatment |
Barbara Rath, France |
December 2019 |
Summarizing Evidence (Ongoing) |
|
|
Microbiological diagnosis of bloodstream infections (ESCMID/ESA) |
Brigitte Lamy, France |
November 2018 |
Developing Recommendations and Determining their Strength (EtDs) (March 2024) |
|
|
Management of uncomplicated urinary tract infections (IDSA/ESCMID) |
Angela Huttner, Switzerland (ESCMID representative) |
April 2018 |
Reporting and peer review (March 2024) |
|
|
Diagnosis and management of infective encephalitis (ESCMID/EAN) |
Thomas Whitfield, United States (ESCMID representative) |
April 2018 |
Public Consultation Phase (December 2024) |
|
|
Management of Staphylococcus aureus bacteremia (IDSA/ESCMID) |
Winfried Kern, Germany and François Vandenesch, France |
January 2017 |
Developing Recommendations and Determining their Strength (EtDs) (March 2024) |
|
The draft document "EAN-ESCMID guidelines on the diagnosis and management of encephalitis in adults caused by infection" is now available for public consultation.
ESCMID members wishing to participate should get in contact with guidancedocuments(at)escmid.org providing their ESCMID membership number and the title of the document they would like to review. Disclaimer: PICO 11 is subject to change following publication of the DexEnceph UK study (but we won't know until then).
By accepting to participate in the public consultation, you agree to commit to confidentiality (you are not allowed to disclose the content or share the manuscript) and to respond within the deadline.
ESCMID will send you the confidential manuscript together with the form to provide feedback (Please comment on substantive content only, not editorial concerns).
You will also be asked to complete the AGREE GLOBAL RATING SCALE form (More information about the AGREE II tool can be found here).
The deadline to provide feedback is 02 January 2025.
The draft document "Clinical Practice Guideline by the Infectious Diseases Society of America: 2024 Guideline Update on the Diagnosis and Management of Intravascular catheter-related infections" is now available for public consultation.
ESCMID members wishing to participate should get in contact with guidancedocuments(at)escmid.org providing their ESCMID membership number and the title of the document they would like to review.
By accepting to participate in the public consultation, you agree to commit to confidentiality (you are not allowed to disclose the content or share the manuscript) and to respond within the deadline.
ESCMID will send you the confidential manuscript together with the form to provide feedback (Please comment on substantive content only, not editorial concerns).
You will also be asked to complete the AGREE GLOBAL RATING SCALE form (More information about the AGREE II tool can be found here).
The deadline to provide feedback is 06 January 2025.